{"id":963,"date":"2026-06-06T08:25:13","date_gmt":"2026-06-06T08:25:13","guid":{"rendered":"https:\/\/genes2me.com\/blog\/?p=963"},"modified":"2026-06-06T09:49:45","modified_gmt":"2026-06-06T09:49:45","slug":"detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing","status":"publish","type":"post","link":"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/","title":{"rendered":"Detect, Differentiate, Quantify: A Complete Approach to BCR-ABL Testing"},"content":{"rendered":"\n
\"\"
BCR-ABL1 Fusion gene<\/figcaption><\/figure>\n\n\n\n

Cancer is one of the leading health challenges worldwide. Among the many forms of cancer, leukemia remains one of the most complex diseases to diagnose and manage. Unlike solid tumors, leukemia affects the blood and bone marrow, disrupting the body’s ability to produce healthy blood cells. Over the years, advances in molecular diagnostics have transformed leukemia care. Molecular diagnostics<\/a> enables clinicians to detect disease-causing genetic abnormalities with remarkable precision. One such breakthrough discovery is the BCR-ABL fusion gene. It is a biomarker that has revolutionized the diagnosis, monitoring, and treatment of certain leukemias.<\/p>\n\n\n\n

What is the BCR-ABL Fusion Gene?<\/strong><\/h4>\n\n\n\n

The BCR-ABL fusion gene is formed due to a genetic rearrangement known as a chromosomal translocation. Specifically, parts of chromosome 9 and chromosome 22 exchange genetic material, creating an abnormal chromosome called the Philadelphia chromosome. During this process, the BCR gene from chromosome 22 fuses with the ABL1 gene from chromosome 9. <\/p>\n\n\n\n

BCR-ABL fusion gene<\/a> produces an abnormal protein called BCR-ABL tyrosine kinase. In normal condition, cellular proteins regulate cell growth in a controlled manner. But this abnormal protein continuously signals cells to divide and multiply. As a result, abnormal white blood cells accumulate in the bone marrow and bloodstream, eventually leading to leukemia.<\/p>\n\n\n\n

How is BCR-ABL Related to Leukemia?<\/strong><\/h4>\n\n\n\n

The BCR-ABL fusion gene is considered the molecular hallmark of Chronic Myelogenous Leukemia (CML). This translocation is detected in >90% of patients with Chronic Myelogenous Leukemia (CML). And ~20% of Acute Lymphoblastic Leukemia (ALL) patients, which predominantly express the p210 and p190 proteins, respectively. Although rare, occasional reports have identified BCR-ABL in certain Acute Myeloid Leukemia (AML) cases.<\/p>\n\n\n\n

BCR-ABL fusion gene not only confirms the diagnosis but also provides critical information regarding disease prognosis and treatment selection.<\/p>\n\n\n\n

Why is BCR-ABL Testing So Important?<\/strong><\/h4>\n\n\n\n

Historically, leukemia diagnosis relied heavily on microscopic examination of blood and bone marrow samples. While these methods remain important, they cannot provide the molecular-level insights required for precision medicine.<\/p>\n\n\n\n

BCR-ABL testing enables clinicians<\/strong> to confirm the diagnosis of CML and certain ALL cases, identify specific transcript variants, establish baseline disease burden and monitor treatment response. It also help to detect minimal residual disease (MRD) and identify disease progression or relapse at an early stage.<\/p>\n\n\n\n

To support these evolving clinical needs, laboratories require diagnostic solutions<\/a> that combine accuracy, sensitivity, and workflow efficiency.<\/p>\n\n\n\n

Comprehensive Detection When It Matters Most<\/strong><\/h4>\n\n\n\n
\"\"
BCR-ABL Universal RT-PCR Kit<\/figcaption><\/figure>\n\n\n\n

The Genes2Me BCR-ABL Universal Real-Time PCR Kit<\/a><\/strong> is to provide a complete molecular picture from the very first test. The kit helps in qualitative detection and differentiation of clinically relevant Major (p210), Minor (p190), and Micro (p230) fusion transcripts<\/strong>. Additionally, it enables precise quantification of Major (p210) transcripts for disease burden evaluation and longitudinal monitoring.<\/p>\n\n\n\n

The kit converts extracted RN<\/a>A<\/a> into cDNA and amplifies it using a one-step qRT-PCR workflow for precise transcript detection and quantification. And uses highly specific primers and fluorescent probes to detect major, minor, and micro fusion transcripts in separate reactions. Fluorescent reporter dyes enable accurate amplification monitoring. It includes a complete set of quantification standards (QS1\u2013QS5) to generate standard curves for reliable quantification of BCR-ABL1 transcript levels.<\/p>\n\n\n\n

By integrating diagnosis and monitoring capabilities within a single workflow, the Universal Kit helps laboratories to generate clinically meaningful results.<\/p>\n\n\n\n

Precision Monitoring for Long-Term Disease Management<\/strong><\/h4>\n\n\n\n
\"\"
BCR-ABL Quantitative RT-PCR Kit<\/figcaption><\/figure>\n\n\n\n

As treatment progresses, accurate quantification becomes increasingly important. The Genes2Me BCR-ABL Quantitative Real-Time PCR Kit<\/a><\/strong> is specifically designed for sensitive and reliable quantification of Major (p210) BCR-ABL1 transcripts. Quantification standards and ABL1-based normalization supports precise measurement of transcript levels, enabling effective treatment monitoring and minimal residual disease assessment.<\/p>\n\n\n\n

Hence, Its robust assay design delivers reproducible results that help clinicians evaluate therapeutic response throughout the patient’s treatment journey.<\/p>\n\n\n\n

Built for Confidence, Designed for Clinical Excellence<\/strong><\/h4>\n\n\n\n

Additionally, Both kits incorporate the ABL1 gene as an internal control<\/strong>, ensuring assay integrity and result reliability. Developed on advanced RT- PCR technology and validated across widely used PCR platforms, these solutions offer the sensitivity, specificity, and consistency required for modern oncology laboratories.<\/p>\n\n\n\n

Driving the Future of Personalized Leukemia Care<\/strong><\/h4>\n\n\n\n

In the era of precision medicine, molecular insights are increasingly shaping treatment strategies. From initial diagnosis and transcript characterization to long-term response monitoring, Genes2Me<\/a>‘s BCR-ABL testing portfolio empowers laboratories with the tools needed to deliver actionable clinical information.<\/p>\n\n\n\n

Because in leukemia management, every result matters, and every molecular insight brings healthcare one step closer to truly personalized oncology care<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Cancer is one of the leading health challenges worldwide. Among the many forms of cancer, leukemia remains one of the most complex diseases to diagnose…<\/p>\n","protected":false},"author":1,"featured_media":969,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[5,234,7,235,265],"tags":[461,462,463,273,453,454,455,464,457,466,459,460,244,243,465,458,456,35,358,352],"yoast_head":"\nBCR-ABL | Leukemia Testing Solution Kit | Fusion Gene | Oncology<\/title>\n<meta name=\"description\" content=\"The BCR-ABL fusion gene is a key molecular marker in blood cancer, particularly Chronic Myeloid Leukemia & certain Acute Lymphoblastic Leukemia cases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BCR-ABL | Leukemia Testing Solution Kit | Fusion Gene | Oncology\" \/>\n<meta property=\"og:description\" content=\"The BCR-ABL fusion gene is a key molecular marker in blood cancer, particularly Chronic Myeloid Leukemia & certain Acute Lymphoblastic Leukemia cases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/\" \/>\n<meta property=\"og:site_name\" content=\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-06T08:25:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-06T09:49:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2026\/06\/BCR-ABL-BANNER-01.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1459\" \/>\n\t<meta property=\"og:image:height\" content=\"1095\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Genes2Me\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Genes2Me\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/genes2me.com\/blog\/#organization\",\"name\":\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\",\"url\":\"https:\/\/genes2me.com\/blog\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg\",\"contentUrl\":\"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg\",\"width\":150,\"height\":69,\"caption\":\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\"},\"image\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/genes2me.com\/blog\/#website\",\"url\":\"https:\/\/genes2me.com\/blog\/\",\"name\":\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\",\"description\":\"Real Time PCR Molecular Diagnostics NGS Cancer Screening Sequencing COVID-19 Rapid Antigen Antibody Made in India Manufacturer Clinical\/Whole Exome\",\"publisher\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/genes2me.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/\",\"url\":\"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/\",\"name\":\"BCR-ABL | Leukemia Testing Solution Kit | Fusion Gene | Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#website\"},\"datePublished\":\"2026-06-06T08:25:13+00:00\",\"dateModified\":\"2026-06-06T09:49:45+00:00\",\"description\":\"The BCR-ABL fusion gene is a key molecular marker in blood cancer, particularly Chronic Myeloid Leukemia & certain Acute Lymphoblastic Leukemia cases.\",\"breadcrumb\":{\"@id\":\"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/genes2me.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Detect, Differentiate, Quantify: A Complete Approach to BCR-ABL Testing\"}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/\"},\"author\":{\"name\":\"Genes2Me\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa\"},\"headline\":\"Detect, Differentiate, Quantify: A Complete Approach to BCR-ABL Testing\",\"datePublished\":\"2026-06-06T08:25:13+00:00\",\"dateModified\":\"2026-06-06T09:49:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/\"},\"wordCount\":740,\"publisher\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#organization\"},\"keywords\":[\"aml\",\"aml solution\",\"aml testing kit\",\"bcr\",\"bcr abl\",\"bcr abl kit\",\"bcr abl solution\",\"bcr abl testing\",\"BCR-ABL fusion gene\",\"BCR-ABL1\",\"cml solution\",\"cml testing kit\",\"g2m\",\"genes2me\",\"kit\",\"leukemia care\",\"oncology assay\",\"RT PCR\",\"rt pcr kit\",\"testing kit\"],\"articleSection\":[\"Diagnostics\",\"Manufacturing\",\"Oncology\",\"Real Time PCR Solutions\",\"RT-PCR IVD Solutions\"],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa\",\"name\":\"Genes2Me\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g\",\"caption\":\"Genes2Me\"},\"description\":\"Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry\u2019s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics\u2014delivering integrated solutions that advance precision medicine and improve lives worldwide.\",\"sameAs\":[\"https:\/\/www.genes2me.com\/\"],\"url\":\"https:\/\/genes2me.com\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BCR-ABL | Leukemia Testing Solution Kit | Fusion Gene | Oncology","description":"The BCR-ABL fusion gene is a key molecular marker in blood cancer, particularly Chronic Myeloid Leukemia & certain Acute Lymphoblastic Leukemia cases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/","og_locale":"en_US","og_type":"article","og_title":"BCR-ABL | Leukemia Testing Solution Kit | Fusion Gene | Oncology","og_description":"The BCR-ABL fusion gene is a key molecular marker in blood cancer, particularly Chronic Myeloid Leukemia & certain Acute Lymphoblastic Leukemia cases.","og_url":"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/","og_site_name":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems","article_published_time":"2026-06-06T08:25:13+00:00","article_modified_time":"2026-06-06T09:49:45+00:00","og_image":[{"width":1459,"height":1095,"url":"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2026\/06\/BCR-ABL-BANNER-01.jpg","type":"image\/jpeg"}],"author":"Genes2Me","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Genes2Me","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/genes2me.com\/blog\/#organization","name":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems","url":"https:\/\/genes2me.com\/blog\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg","contentUrl":"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg","width":150,"height":69,"caption":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems"},"image":{"@id":"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/"}},{"@type":"WebSite","@id":"https:\/\/genes2me.com\/blog\/#website","url":"https:\/\/genes2me.com\/blog\/","name":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems","description":"Real Time PCR Molecular Diagnostics NGS Cancer Screening Sequencing COVID-19 Rapid Antigen Antibody Made in India Manufacturer Clinical\/Whole Exome","publisher":{"@id":"https:\/\/genes2me.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/genes2me.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/","url":"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/","name":"BCR-ABL | Leukemia Testing Solution Kit | Fusion Gene | Oncology","isPartOf":{"@id":"https:\/\/genes2me.com\/blog\/#website"},"datePublished":"2026-06-06T08:25:13+00:00","dateModified":"2026-06-06T09:49:45+00:00","description":"The BCR-ABL fusion gene is a key molecular marker in blood cancer, particularly Chronic Myeloid Leukemia & certain Acute Lymphoblastic Leukemia cases.","breadcrumb":{"@id":"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/genes2me.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Detect, Differentiate, Quantify: A Complete Approach to BCR-ABL Testing"}]},{"@type":"Article","@id":"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/#article","isPartOf":{"@id":"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/"},"author":{"name":"Genes2Me","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa"},"headline":"Detect, Differentiate, Quantify: A Complete Approach to BCR-ABL Testing","datePublished":"2026-06-06T08:25:13+00:00","dateModified":"2026-06-06T09:49:45+00:00","mainEntityOfPage":{"@id":"https:\/\/genes2me.com\/blog\/2026\/06\/06\/detect-differentiate-quantify-a-complete-approach-to-bcr-abl-testing\/"},"wordCount":740,"publisher":{"@id":"https:\/\/genes2me.com\/blog\/#organization"},"keywords":["aml","aml solution","aml testing kit","bcr","bcr abl","bcr abl kit","bcr abl solution","bcr abl testing","BCR-ABL fusion gene","BCR-ABL1","cml solution","cml testing kit","g2m","genes2me","kit","leukemia care","oncology assay","RT PCR","rt pcr kit","testing kit"],"articleSection":["Diagnostics","Manufacturing","Oncology","Real Time PCR Solutions","RT-PCR IVD Solutions"],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa","name":"Genes2Me","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g","caption":"Genes2Me"},"description":"Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry\u2019s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics\u2014delivering integrated solutions that advance precision medicine and improve lives worldwide.","sameAs":["https:\/\/www.genes2me.com\/"],"url":"https:\/\/genes2me.com\/blog\/author\/admin\/"}]}},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts\/963"}],"collection":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/comments?post=963"}],"version-history":[{"count":10,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts\/963\/revisions"}],"predecessor-version":[{"id":982,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts\/963\/revisions\/982"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/media\/969"}],"wp:attachment":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/media?parent=963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/categories?post=963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/tags?post=963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}